<DOC>
	<DOCNO>NCT00674362</DOCNO>
	<brief_summary>To assess clinical efficacy safety certolizumab pegol add-on therapy stable-dose disease-modifying antirheumatic drug ( DMARDs ) achieve clinical remission patient moderate low disease activity rheumatoid arthritis</brief_summary>
	<brief_title>Rheumatoid Arthritis ( RA ) Moderate Low Disease Activity Study</brief_title>
	<detailed_description>Treatment period start 24-week , double blind , placebo-controlled , randomized period follow open label phase week 52 . In double blind phase eligible patient randomize via Interactive Voice Response System ( IVRS ) 1:1 ratio receive either certolizumab pegol ( 400 mg Weeks 0 , 2 4 , follow 200 mg every two week ) placebo include Week 22 . All patient continue receive Disease Modifying AntiRheumatic Drugs ( DMARDs ) therapy establish study entry Week 52 . At Week 24 , patient receive injection evaluate : - Non-remitters Week 24 ( patient achieve remission Week 20 Week 24 ) discontinue study may give opportunity enter open-label follow-up trial , C87080 [ NCT00843778 ] , certolizumab pegol . - Remitters ( i.e . patient achieve remission measure Clinical Disease Activity Index ( CDAI ) Week 20 Week 24 ) stop randomize treatment ( certolizumab pegol placebo ) follow Week 52 . Remitters flare ( CDAI â‰¥11 confirm two consecutive visit four week apart ) Week 24 Week 52 re-treated dose regimen certolizumab pegol ( 3 administration 400mg , give every 2 week , follow 200 mg give every week ) include Week 50 . Remitters flare Week 24 Week 52 complete 52-week study period allow enter open label follow trial Week 52 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients establish diagnosis low moderate adult rheumatoid arthritis , currently Disease Modifying AntiRheumatic Drugs ( DMARDs ) therapy least six month longer 10 year All concomitant disease pathological condition could interfere impact assessment study treatment , safety patient Previous clinical trial previous biological therapy could interfere result present clinical trial Patients must receive previous biological therapy rheumatoid arthritis ( RA )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Moderate Low Disease activity</keyword>
	<keyword>Certolizumab pegol</keyword>
</DOC>